There is widespread feeling in patent departments of corporations around the country that Kearns' case represents a frightening precedent.

But the only way poor countries can get drugs that result from Shared patent rights is if another country exports those medicines to them under emergency exceptions.

While the EPO provides a common entry point to obtain patents throughout Europe, patent owners must still validate and, where necessary, translate patents in each individual EU country.